At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PLSE Pulse Biosciences
Post-Mkt 11-13 17:57:33 EST
50.44
-1.81
-3.46%
盘后50.10
-0.34-0.67%
16:57 EST
High54.25Low50.20Vol590.64K
Open52.53D1 Closing52.25Amplitude7.75%
Mkt Cap3.71BTradable Cap1.15BTotal Shares73.55M
T/O30.43MT/O Rate2.58%Tradable Shares22.88M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Pulse Biosciences (PLSE) Stock Looks Overvalued Even With Clinical Progress
Simply Wall St.  ·  11-13 17:28
Pulse Biosciences (PLSE) Stock Looks Overvalued Even With Clinical Progress
Pulse Biosciences (PLSE) On Thyroid Data And Losses Has An Undervalued Narrative
Simply Wall St.  ·  11-10
Pulse Biosciences (PLSE) On Thyroid Data And Losses Has An Undervalued Narrative
What Does Pulse Biosciences (PLSE) Mean For Investors After Two Clinical Milestones?
Simply Wall St.  ·  11-07
What Does Pulse Biosciences (PLSE) Mean For Investors After Two Clinical Milestones?
Pulse Biosciences is Maintained at Buy by Canaccord Genuity
Dow Jones  ·  11-07
Pulse Biosciences is Maintained at Buy by Canaccord Genuity
Pulse Biosciences price target raised to $65 from $55 at Mizuho
TIPRANKS  ·  11-06
Pulse Biosciences price target raised to $65 from $55 at Mizuho
Needham Raises Price Target on Pulse Biosciences to $64 From $58, Keeps Buy Rating
MT Newswires Live  ·  11-06
Needham Raises Price Target on Pulse Biosciences to $64 From $58, Keeps Buy Rating
Pulse Biosciences Reports 86% Meet Thyroid Nodule Reduction Target in Six-Month Interim Study Results
Reuters  ·  11-06
Pulse Biosciences Reports 86% Meet Thyroid Nodule Reduction Target in Six-Month Interim Study Results
Pulse Biosciences, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Reuters  ·  11-06
Pulse Biosciences, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Earnings Flash (PLSE) Pulse Biosciences Posts Q3 Loss $0.32 a Share, vs. FactSet Est of $0.37 Loss
MT Newswires Live  ·  11-06
Earnings Flash (PLSE) Pulse Biosciences Posts Q3 Loss $0.32 a Share, vs. FactSet Est of $0.37 Loss
Pulse Biosciences Q3 Net Loss Widens 19% Year over Year to $23.05 Million
Reuters  ·  11-06
Pulse Biosciences Q3 Net Loss Widens 19% Year over Year to $23.05 Million
Pulse Biosciences Q3 EPS $(0.32) Beats $(0.36) Estimate, Sales $395.000K Miss $516.667K Estimate
Benzinga Earnings  ·  11-06
Pulse Biosciences Q3 EPS $(0.32) Beats $(0.36) Estimate, Sales $395.000K Miss $516.667K Estimate
Pulse Biosciences Q3 Net Income USD -23.051 Million
Reuters  ·  11-06
Pulse Biosciences Q3 Net Income USD -23.051 Million
Pulse Biosciences Q3 EPS USD -0.32
THOMSON REUTERS  ·  11-06
Pulse Biosciences Q3 EPS USD -0.32
Pulse Biosciences to Present at Stifel Healthcare Conference
Reuters  ·  10-30
Pulse Biosciences to Present at Stifel Healthcare Conference
Earning Preview: Pulse Biosciences Q3 revenue is expected to increase by 3.33%, and institutional views are cautious
Earnings Agent  ·  10-29
Earning Preview: Pulse Biosciences Q3 revenue is expected to increase by 3.33%, and institutional views are cautious
Pulse Biosciences Schedules Third-Quarter Results Conference Call
Reuters  ·  10-23
Pulse Biosciences Schedules Third-Quarter Results Conference Call
Pulse Biosciences Collaborates With Clayman Thyroid Center on Thyroid Nodule Treatment
MT Newswires Live  ·  10-14
Pulse Biosciences Collaborates With Clayman Thyroid Center on Thyroid Nodule Treatment
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
THOMSON REUTERS  ·  10-14
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says
MT Newswires Live  ·  10-14
Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says
Pulse Biosciences is Maintained at Outperform by Oppenheimer
Dow Jones  ·  10-13
Pulse Biosciences is Maintained at Outperform by Oppenheimer

Introduction

Company Name.
Pulse Biosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.
Issue price:
--